Replies to post #4392 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[tykundegex]

That's my assumption yes.. that because of the generics that will compete (albeit with a major disadvantage), KIT-302 seems (to me) unlikely to get to Celebrex's peak. But hey.. I'm certainly open to other opinions -- that's why I'm here .. to learn from others.

Maybe their market study, or the research paper by LifeSci Capital, has me tempering my enthusiasm. ;-)

In any case, I'm long and very bullish.